Johnson & JohnsonJNJ
ImmunologyMetabolicOncologyPsychiatry160 cited findings · profile updated 2026-08-26
270.36 USDnot live — refreshed daily
About Johnson & Johnson
Johnson & Johnson (JNJ) is active in oncology research. The company's oncology portfolio includes drugs studied for various conditions, with reported efficacy and safety profiles. For instance, in the MARIPOSA study, Amivantamab + Lazertinib showed an incidence of all grades of Rash in 373 cases, while Osimertinib had 210 cases. Grade >=3 Pneumonitis/ILD was observed in 6 cases for Amivantamab + Lazertinib in MARIPOSA, 7 for Lazertinib, and 6 for Osimertinib. Additionally, Grade 3+ Hypoalbuminemia incidence in Amivantamab + Lazertinib (MARIPOSA) was 22, compared to 0 for Osimertinib and Lazertinib.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Grade 3+ Pneumonia incidence | 16 in Amivantamab + Lazertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.120 |
| Grade 3+ Pneumonia incidence | 20 in Osimertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.120 |
| Grade 3+ Hypoalbuminemia incidence | 22 in Amivantamab + Lazertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.120 |
| Grade 3+ Hypoalbuminemia incidence | 0 in Osimertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.120 |
| Incidence (all grades) of Rash | 373 in Amivantamab + Lazertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.121 |
| Incidence (all grades) of Rash | 210 in Osimertinib (MARIPOSA) | Johnson & Johnson — Lazcluze EMA EPAR public assessment report (EMEA/H, p.121 |
Key projects
- Amivantamab + Lazertinib (oncology) — EU
In the MARIPOSA study, Grade 3+ Pneumonia incidence was 16 for Amivantamab + Lazertinib.
- Osimertinib (oncology) — EU
In the MARIPOSA study, Grade 3+ Pneumonia incidence was 20 for Osimertinib.
- Amivantamab (oncology) — EU
Grade 3+ Dyspnea incidence was 19 for Amivantamab.
- Lazertinib (oncology) — EU
Grade >=3 Pneumonitis/ILD was 7 for Lazertinib.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →